In a report released today, Charles Rhyee from TD Cowen maintained a Hold rating on Teladoc (TDOC – Research Report), with a price target of $8.00.
Charles Rhyee has given his Hold rating due to a combination of factors related to Teladoc’s financial outlook and market performance. The company’s adjusted EBITDA for 2025 is projected to be $285 million, which aligns with management’s guidance range. This suggests a stable financial position but not significant growth, as the Integrated Care segment is expected to see only modest revenue growth of 2.4% year-over-year.
Additionally, the BetterHelp segment is anticipated to experience a revenue decline of 7.5% year-over-year, indicating challenges in the U.S. market despite international growth. The overall revenue estimates for 2025 and 2026 show slight increases, but the adjusted EBITDA projections have been revised downward. These factors, combined with a maintained price target of $8 based on discounted cash flow analysis, suggest that the stock is fairly valued at present, justifying the Hold rating.
In another report released on March 6, Truist Financial also reiterated a Hold rating on the stock with a $10.00 price target.